Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves
Danaher topped Q3 earnings estimates at $2.11 per share on $6.55 billion revenue, raising its full-year 2026 adjusted EPS outlook on steady biopharma demand.
Share
Why It Matters
Danaher made more money than expected this quarter. They also raised their forecast because customers keep buying their products.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.